G1 Therapeutics, Inc.

Ownership Transactions Reported by 18 Insiders

Symbol
GTHX on Nasdaq
Industry
Pharmaceutical Preparations
Location
700 Park Offices Drive, Suite 200, Research Triangle Park, North Carolina

Insiders trading volume in the past year

G1 Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
John E. Bailey President and CEO, Director $2.38 M -$330 K -12.2% Jul 1, 2024
Mark Avagliano Chief Business Officer $1.04 M -$51.6 K -4.71% Jul 1, 2024
Glenn P. Muir Director $876 K Jun 13, 2024
W. Umstead John Chief Financial Officer $803 K -$61.1 K -7.07% Jul 1, 2024
Rajesh Malik Chief Medical Officer $775 K -$302 K -28% May 13, 2024
Monica Thomas Chief Legal & People Officer $618 K -$24.9 K -3.87% Jul 1, 2024
Terry L. Murdock Chief Operating Officer $557 K -$53.9 K -8.83% Jul 1, 2024
Andrew Perry Chief Commercial Officer $486 K -$47.4 K -8.89% Jul 1, 2024
Mark A. Velleca Director $341 K -$120 K -26% Aug 8, 2023
Jennifer K. Moses Cfo $170 K Jan 3, 2023
Cynthia Louise Flowers Director $153 K Jun 13, 2024
Garry A. Nicholson Director $147 K Jun 13, 2024
Alicia Secor Director $128 K Jun 13, 2024
James S. Hanson General Counsel $121 K Jan 3, 2023
Norman Sharpless Director $85.4 K Jun 13, 2024
Jacks Lee Director $85.4 K Jun 13, 2024
Willie A. Deese Director $42.3 K Jun 23, 2022
Seth Rudnick Director $28.4 K Jun 29, 2021

Recent Insider Transactions by Companies or Individuals for G1 Therapeutics, Inc.

Insider Class Transaction % Value $ Price $ Shares Shares Owned Date Ownership